On Assignment, Inc. — Q3 2011 Form 10-Q
Entity note: The filing identifies the registrant as On Assignment, Inc.; it does not identify Everforth Inc. The report covers the quarter and nine months ended September 30, 2011. Financial statements are unaudited; amounts below are in millions except per-share data.
Business context and reporting period
On Assignment provides temporary and permanent professional staffing through four segments: Life Sciences, Healthcare, Physician, and IT and Engineering. Management said demand strengthened across all segments in Q3. The company acquired Valesta in February and HealthCare Partners (HCP) on July 31, 2011; their results are included from their respective acquisition dates.
Financial performance
| Metric | Q3 2011 | Q3 2010 | Nine months 2011 | Nine months 2010 |
|---|---|---|---|---|
| Revenue | $162.4 | $116.1 | $435.5 | $316.9 |
| Gross profit | $54.5 | $41.1 | $146.5 | $107.2 |
| Operating income | $13.7 | $7.4 | $30.9 | $11.8 |
| Net income | $7.8 | $3.2 | $16.8 | $3.8 |
| Diluted EPS | $0.21 | $0.09 | $0.44 | $0.10 |
| Gross margin | 33.6% | 35.4% | 33.6% | 33.8% |
| Operating margin | 8.5% | 6.4% | 7.1% | 3.7% |
- Q3 revenue increased 39.8% year over year; nine-month revenue rose 37.4%. Q3 revenue included $6.0 million from Valesta and $4.5 million from HCP. Acquisitions contributed $31.0 million to nine-month 2011 revenue, versus $6.3 million in the comparable 2010 period.
- Q3 consolidated gross margin contracted 180 basis points; the nine-month margin declined 20 basis points. Management cited lower direct-hire and conversion-fee revenue mix, the expiration of 2010 HIRE Act payroll tax credits, and a greater share of lower-margin Nurse Travel revenue. SG&A declined as a percentage of revenue, supporting higher operating margins.
- For Q3, all segments grew revenue: Life Sciences 39.1%, Healthcare 36.4%, Physician 24.5%, and IT and Engineering 47.7%. Physician revenue growth largely reflected HCP; legacy physician staffing was essentially flat. IT and Engineering was the largest segment by revenue.
- Nine-month operating cash flow was $15.1 million, down from $20.4 million. The company attributed the decline mainly to increased operating assets and liabilities, particularly accounts receivable, amid growth. Investing cash outflow was $38.5 million, including $32.8 million for acquisitions and $6.0 million in capital expenditures. Financing provided $18.4 million, including $40.5 million of revolving-credit borrowings.
- At September 30, cash was $13.2 million, working capital was $59.0 million, and total debt was $88.0 million, up from $66.8 million at December 31, 2010. The company reported compliance with all financial covenants. The $75 million revolving facility had $43 million outstanding; the $50 million term loan had $45 million outstanding.
Changes, outlook, risks and contingencies
- Management expected 2011 capital expenditures of approximately $8.1 million, of which $6.0 million had been spent through September. It believed working capital, the credit facility, and expected operating cash flows would fund obligations and planned requirements for the next 12 months. No earnings or revenue guidance was provided.
- Management described improving demand and economic trends, while noting that Healthcare remained soft and legacy physician staffing faced uncertainty related to healthcare reform, economic conditions, physician retirement patterns, and lower elective procedures. Staffing demand is typically seasonally weaker in Q1 and Q4.
- Potential future acquisition earn-outs were approximately $11.1 million through 2013. The HCP and Valesta purchase price allocations remained preliminary. The company used a $25 million interest-rate swap to hedge part of its floating-rate debt exposure; after the hedge, a 1 percentage-point rate change was estimated to alter annual interest expense by about $0.6 million.
- Workers’ compensation and medical malpractice self-insurance reserves were approximately $10.2 million. The company reported ordinary-course legal matters and did not believe their resolution would materially adversely affect its financial position, results, or cash flows. The IRS had begun examining the company’s 2009 U.S. income tax return.
- Management cited risks including economic conditions, demand for services, recruiting and retaining qualified professionals, competition, growth management, and information systems. It reported effective disclosure controls and no material change in internal control over financial reporting.
- Unusual or period-specific factors included favorable medical malpractice claims development benefiting Physician gross profit, prior-year HIRE Act credits that did not recur, labor-disruption staffing revenue in Healthcare, and a $1.3 million gain from settling the Cambridge earn-out included in nine-month results.
Important facts for investors to verify
- Confirm the registrant identity: the supplied filing is for On Assignment, Inc., not Everforth Inc.
- Assess how much reported growth reflects acquisitions versus organic demand, particularly in Life Sciences and Physician.
- Monitor gross-margin pressure, especially in Healthcare and IT and Engineering, and the sustainability of improved operating margins.
- Review receivables, operating cash flow, debt levels, covenant headroom, and the cash requirements for earn-outs and acquisitions.
- Track the final HCP and Valesta purchase accounting, earn-out performance, and any subsequent changes to acquisition-related goodwill or intangible assets.